Compare SBET & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | ABCL |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2025 | 2020 |
| Metric | SBET | ABCL |
|---|---|---|
| Price | $6.28 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $18.71 | $8.40 |
| AVG Volume (30 Days) | 6.3M | ★ 8.8M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | $28,055,000.00 | ★ $75,128,000.00 |
| Revenue This Year | $105.19 | N/A |
| Revenue Next Year | $13.53 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | 160.56 |
| 52 Week Low | $5.96 | $1.97 |
| 52 Week High | $124.12 | $6.52 |
| Indicator | SBET | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 64.05 |
| Support Level | $6.05 | $3.32 |
| Resistance Level | $8.20 | $5.63 |
| Average True Range (ATR) | 0.37 | 0.45 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 9.37 | 73.67 |
SharpLink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.